A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors.
S Lindsey DavisWells A MessersmithW Thomas PurcellElaine T LamBradley R CorrAlexis D LealChristopher H LieuCindy L O'BryantStephen G SmootsEvan D DusKimberly R JordanNatalie J SerkovaTodd M PittsJennifer R DiamondPublished in: Cancers (2024)
Dual targeting of Aurora A kinase and mTOR resulted in marginal clinical benefit in a population of patients with refractory solid tumors, including pancreatic adenocarcinoma, though individual patients experienced significant response to therapy. Correlatives indicate apoptotic response and tumor immune cell infiltrate may affect clinical outcomes.